“Innovations DivisionThe Innovation Division continues to be primarily focused on its flagship project, being the commercialisation of the Sr-HT-Gahnite Cervical Spinal Cage. This project continues to see positive results. Allegra remains on track to submit this project for regulatory 510k approval with the US Federal Drug Administration (FDA) on or around 31st March 2023.”
- Forums
- ASX - By Stock
- Ann: Company Update Correction
“Innovations DivisionThe Innovation Division continues to be...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AMT (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.468M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AMT (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online